VERAXA Biotech AG (NASDAQ: VRXA) has advanced its VXA-222 bispecific antibody-drug conjugate (ADC) program beyond the initial discovery phase, following the completion of its collaboration with OmniAb. The company now plans to engineer the final candidate using its antibody-engineering, linker and conjugation technologies and to conduct in vitro and in vivo preclinical studies, according to a recent announcement.
The move marks a significant step for VERAXA as it seeks to build a premier engine for next-generation antibody-based therapeutics. VXA-222 employs an “AND-gate” design intended to recognize two tumor-associated antigens simultaneously, potentially increasing selectivity for cancer cells while sparing healthy tissue. This dual-targeting approach could address a key challenge in oncology: improving the precision of ADCs, which combine the targeting ability of antibodies with the cell-killing power of cytotoxic drugs.
VERAXA’s broader oncology pipeline spans ADCs, T-cell engagers and other engineered antibody formats. The company has also filed its first patents covering its BiTAC-TCE and BiTAC-ADC platforms and related payload, click-chemistry and conjugation technologies. These filings add to an intellectual-property portfolio that includes more than 50 granted patents across 26 families in 14 countries, underscoring the company’s commitment to protecting its innovations as it moves programs toward clinical development.
For investors, the advancement of VXA-222 signals progress in a high-potential area of cancer therapy. Bispecific ADCs are a growing focus in the biopharma industry because they may offer enhanced efficacy and reduced side effects compared to traditional treatments. VERAXA’s proprietary BiTAC formats and its suite of transformative technologies position it to compete in this evolving landscape.
The company was founded on scientific breakthroughs made at the European Molecular Biology Laboratory, a world-renowned institution known for pioneering life science research. More information about VERAXA Biotech is available at www.VERAXA.com, and the full article can be viewed at https://ibn.fm/S3tyP. Regular updates relating to VRXA are available in the company’s newsroom at https://nnw.fm/VRXA.
The announcement was distributed through InvestorWire, a specialized communications platform focused on wire-grade press release syndication. InvestorWire is part of the Dynamic Brand Portfolio at IBN, which provides access to a vast network of wire solutions, article and editorial syndication to 5,000+ outlets, enhanced press release enhancement, social media distribution and tailored corporate communications solutions. Terms of use and disclaimers are available at https://www.InvestorWire.com/Disclaimer.
